BIO-RAD LABORATORIES, INC. - 8-K Filing

Bio-Rad reports Q3 2026 net income of $458.6 million driven by Sartorius AG investment fair market value change. (Items: 2.02 Results of Operations and Financial ConditionOn November 4, 2026, Bio-Rad Laboratories, Inc, 7.01 Regulation FD DisclosureAlso on November 4, 2026, the Company posted supplemental earnings materials with respect to its financial results fo, 9.01 Financial Statements and ExhibitsExhibitNumber Description99)

SEC EDGAR · November 4, 2026, 21:16 UTC

Tickers: $BIO

Read the full article at SEC EDGAR

More Regulatory news

CENTRUS ENERGY CORP - 8-K Filing SEC EDGAR · November 12, 2026, 14:09 UTC
SAGA COMMUNICATIONS INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
NextBoat Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
CIVISTA BANCSHARES, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
RF Acquisition Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 14:04 UTC
ORASURE TECHNOLOGIES INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Rocket Companies, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Applied Aerospace & Defense, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:02 UTC
Palomar Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:02 UTC
UNITED GUARDIAN INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:00 UTC